PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Latest Information Update: 23 May 2025
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PLATI-PARP
Most Recent Events
- 16 May 2025 Planned End Date changed from 15 May 2025 to 4 Jun 2025.
- 16 May 2025 Planned primary completion date changed from 15 May 2025 to 4 Jun 2025.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology